A systematic review of euthyroid Graves' disease (Review)

Macovei,Mioara-Laura; Azis,Űnal; Gheorghe,Alina Gabriela; Burcea,Marian

doi:10.3892/etm.2021.10781

A systematic review of euthyroid Graves' disease (Review)

Authors:
- Mioara-Laura Macovei
- Űnal Azis
- Alina Gabriela Gheorghe
- Marian Burcea
View Affiliations

Affiliations: Department of Ophthalmology, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania
Published online on: September 22, 2021 https://doi.org/10.3892/etm.2021.10781
Article Number: 1346
Copyright: © Macovei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Euthyroid Graves' Disease (EGD) is a challenging pathology, due to its atypical clinical manifestations and the absence of abnormal thyroid function. Typically, thyroid ophthalmopathy is associated with elevated thyroid hormone levels and with the presence of thyrotropin receptor antibodies (TRAb) but a low percentage of patients remain euthyroid without developing hyperthyroidism during long‑term follow‑up periods. Although it is considered a different pathology, it shares a lot of similarities with Graves' disease, rendering the diagnosis more difficult. It is also important to note that ophthalmopathy may be the first clinical manifestation of Graves' disease and that thyroid function examinations do not present abnormalities over a long period. Treatment choices for euthyroid disease do not differ from those described in Graves' ophthalmopathy. However, it is considered that since euthyroid patients develop milder ophthalmic symptoms and their clinical activity score is lower, they tend to have better responses to treatment. Moreover, atypical sight‑threatening cases such as exposure keratopathy and dysthyroid optic neuropathy with variable responses to therapy also exist. Disease management consists of a favorable collaboration between ophthalmologists and endocrinologists because patients with EGD can develop thyroid abnormalities over time. In conclusion, the diagnosis of EGD is difficult, clinical manifestations and evolution are variables depending on several factors, including the heterogeneity of TRAb. This review aimed to identify the characteristics of this disease by reviewing the clinical studies and case reports published in previous years.

View Figures

View References

1	Wang Y and Smith TJ: Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci. 55:1735–1748. 2014.PubMed/NCBI View Article : Google Scholar
2	Muñoz-Ortiz J, Sierra-Cote MC, Zapata-Bravo E, Valenzuela-Vallejo L, Marin-Noriega MA, Uribe-Reina P, Terreros-Dorado JP, Gómez-Suarez M, Arteaga-Rivera K and de-la-Torre A: Prevalence of hyperthyroidism, hypothyroidism, and euthyroidism in thyroid eye disease: A systematic review of the literature. Syst Rev. 9(201)2020.PubMed/NCBI View Article : Google Scholar
3	Jang SY, Lee SY, Lee EJ and Yoon JS: Clinical features of thyroid-associated ophthalmopathy in clinically euthyroid Korean patients. Eye (Lond). 26:1263–1269. 2012.PubMed/NCBI View Article : Google Scholar
4	Boddu N, Jumani M, Wadhwa V, Bajaj G and Faas F: Not all orbitopathy is Graves': Discussion of cases and review of literature. Front Endocrinol (Lausanne). 8(184)2017.PubMed/NCBI View Article : Google Scholar
5	Termote K, Decallonne B and Mombaerts I: The influence of prior hyperthyroidism on euthyroid graves' ophthalmopathy. J Ophthalmol. 2014(426898)2014.PubMed/NCBI View Article : Google Scholar
6	Peter SA: Euthyroid Graves' disease. Report of a case observed over a 12-year period. Am J Med. 80:1197–1198. 1986.PubMed/NCBI View Article : Google Scholar
7	Bhatnagar A, Tsirbas A, Douglas RS, Goldberg RA and Hoyama E: Graves' orbitopathy. Ophthalmology. 114:392.e1–e2. 2007.PubMed/NCBI View Article : Google Scholar
8	Kavoussi SC, Giacometti JN, Javier Servat JJ and Levin F: The relationship between sex and symmetry in thyroid eye disease. Clin Ophthalmol. 8:1295–1300. 2014.PubMed/NCBI View Article : Google Scholar
9	Bartalena L and Piantanida E: Cigarette smoking: Number one enemy for Graves ophthalmopathy. Pol Arch Med Wewn. 126:725–726. 2016.PubMed/NCBI View Article : Google Scholar
10	Takasu N, Oshiro C, Akamine H, Komiya I, Nagata A, Sato Y, Yoshimura H and Ito K: Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects. J Endocrinol Invest. 20:452–461. 1997.PubMed/NCBI View Article : Google Scholar
11	Gerding MN, Van Der Meer JW, Broenink M, Bakker O, Wiersinga WM and Prummel MF: Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf). 52:267–271. 2000.PubMed/NCBI View Article : Google Scholar
12	Inoue D, Sato K, Maeda M, Inoko H, Tsuji K, Mori T and Imura H: Genetic differences shown by HLA typing among Japanese patients with euthyroid Graves' ophthalmopathy, Graves' disease and Hashimoto's thyroiditis: Genetic characteristics of euthyroid Graves' ophthalmopathy. Clin Endocrinol (Oxf). 34:57–62. 1991.PubMed/NCBI View Article : Google Scholar
13	Ardley M, McCorquodale T, Lahooti H, Champion B and Wall JR: Eye findings and immunological markers in probands and their euthyroid relatives from a single family with multiple cases of thyroid autoimmunity. Thyroid Res. 5(4)2012.PubMed/NCBI View Article : Google Scholar
14	Khoo TK and Bahn RS: Pathogenesis of Graves' ophthalmopathy: The role of autoantibodies. Thyroid. 17:1013–1018. 2007.PubMed/NCBI View Article : Google Scholar
15	Stan MN, Garrity JA and Bahn RS: The evaluation and treatment of Graves ophthalmopathy. Med Clin North Am. 96:311–328. 2012.PubMed/NCBI View Article : Google Scholar
16	Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM and Prummel MF: TSH-R expression and cytokine profile in orbital tissue of active vs inactive Graves' ophthalmopathy patients. Clin Endocrinol (Oxf). 58:280–287. 2003.PubMed/NCBI View Article : Google Scholar
17	Gopinath B, Musselman R, Beard N, El-Kaissi S, Tani J, Adams CL and Wall JR: Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves' disease. Clin Exp Immunol. 145:56–62. 2006.PubMed/NCBI View Article : Google Scholar
18	Krishnan VM, Baba D, Kumar KR and Venkatesh P: Case report a case of unilateral euthyroid Graves' disease. Sch J App Med Sci. 3:2534–2536. 2015.
19	Kotwal A and Stan M: Thyrotropin receptor antibodies-an overview. Ophthal Plast Reconstr Surg. 34 (Suppl 1):S20–S27. 2018.PubMed/NCBI View Article : Google Scholar
20	Bartley GB and Gorman CA: Diagnostic criteria for Graves' ophthalmopathy. Am J Ophthalmol. 119:792–795. 1995.PubMed/NCBI View Article : Google Scholar
21	Bartley G: Rundle and His Curve. Arch Ophthalmol. 129:356–358. 2011.PubMed/NCBI View Article : Google Scholar
22	Marinò M, Barbesino G, Pinchera A, Manetti L, Ricciardi R, Rossi B, Muratorio A, Braverman LE, Mariotti S and Chiovato L: Increased frequency of euthyroid ophthalmopathy in patients with Graves' disease associated with myasthenia gravis. Thyroid. 10:799–802. 2000.PubMed/NCBI View Article : Google Scholar
23	Komoto N, Kozaki A, Yu F, Inoue R, Maeda T, Inoue T and Inoue Y: Clinical feature of euthyroid Graves' ophthalmopathy. Invest Ophthalmol Vis Sci. 49(5250)2008.
24	Eckstein AK, Lösch C, Glowacka D, Schott M, Mann K, Esser J and Morgenthaler NG: Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy. Br J Ophthalmol. 93:1052–1056. 2009.PubMed/NCBI View Article : Google Scholar
25	Wiersinga WM, Smit T, van der Gaag R and Koornneef L: Temporal relationship between onset of Graves' ophthalmopathy and onset of thyroidal Graves' disease. J Endocrinol Invest. 11:615–619. 1988.PubMed/NCBI View Article : Google Scholar
26	Cakir M: Euthyroid Graves' ophthalmopathy with negative autoantibodies. J Natl Med Assoc. 97:1547–1549. 2005.PubMed/NCBI
27	Hegedüs L, Bonnema SJ, Smith TJ and Brix TH: Treating the thyroid in the presence of Graves' ophthalmopathy. Best Pract Res Clin Endocrinol Metab. 26:313–324. 2012.PubMed/NCBI View Article : Google Scholar
28	Khoo DH, Eng PH, Ho SC, Tai ES, Morgenthaler NG, Seah LL, Fong KS, Chee SP, Choo CT and Aw SE: Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: Prevalence, natural history, and thyrotropin receptor antibody levels. Thyroid. 10:1093–1100. 2000.PubMed/NCBI View Article : Google Scholar
29	Watanabe M, Iwatani Y, Kashiwai T, Iijima T, Fujikado T and Amino N: Euthyroid Graves' disease showing no thyroid abnormalities except positive thyroid-sstimulating antibody (TSAb): Two case reports. J Intern Med. 238:379–384. 1995.PubMed/NCBI View Article : Google Scholar
30	Tanaka K, Nomura T, Ohta Y, et al: A case of euthyroid Graves disease which developed into Graves disease with thyrotoxicosis after subacute thyroiditis. The Endocrinologist. 19:124–125. 2009.
31	Majumder A and Chatterjee S: Euthyroid Graves' ophthalmopathy patients remaining stable on more than 20 months follow up-a report of 9 patients. Hot Thyroidol. 2019.
32	Hotta A, Tanaka T, Kato H, Kakoi S, Shimizu Y, Hasegawa C, Hayakawa A, Yasuda S, Ogawa K, Ito S, et al: A case of euthyroid Graves' ophthalmopathy in a patient sero-negative for TSH receptor autoantibody. Case Rep Endocrinol. 2018(1707959)2018.PubMed/NCBI View Article : Google Scholar
33	Tabasum A, Khan I, Taylor P, Das G and Okosieme OE: Thyroid antibody-negative euthyroid Graves' ophthalmopathy. Endocrinol Diabetes Metab Case Rep. 2016(160008)2016.PubMed/NCBI View Article : Google Scholar
34	Shah Y: Thyroid ophthalmopathy. J Assoc Physicians India. 59 (Suppl 1):S60–S65. 2011.PubMed/NCBI
35	Arslan E, Yavaşoǧlu I, Çildaǧ BM and Kocatürk T: Unilateral optic neuropathy as the initial manifestation of euthyroid Graves' disease. Intern Med. 48:1993–1994. 2009.PubMed/NCBI View Article : Google Scholar
36	Lee YC, Chang FL and Tsai RK: Intravenous pulse corticosteroid therapy in euthyroid optic neuropathy: A case report. Neuro Ophthalmol. 36:143–145. 2012.
37	Kitaguchi Y, Ishihara K and Nishida K: Spontaneous resolution of euthyroid optic neuropathy. Can J Ophthalmol. 54:e188–e192. 2019.PubMed/NCBI View Article : Google Scholar
38	Dickinson AJ and Perros P: Controversies in the clinical evaluation of active thyroid-associated orbitopathy: Use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf). 55:283–303. 2001.PubMed/NCBI View Article : Google Scholar
39	Kakizaki H, Zako M and Iwaki M: Thyroid-associated inferior oblique myopathy. Ophthalmology. 114(2106)2007.PubMed/NCBI View Article : Google Scholar
40	Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M and Wiersinga WM: European Group on Graves' Orbitopathy (EUGOGO). The 2016 European thyroid association/European group on Graves' orbitopathy guidelines for the management of Graves' orbitopathy. Eur Thyroid J. 5:9–26. 2016.PubMed/NCBI View Article : Google Scholar
41	Wawhal M, Mogal V, Patil P, Ahire P and Yadav S: Euthyroid ophthalmopathy: A rare case report and a brief review of literature. Int J Sci Res. 4:529–532. 2015.
42	Ursu HI, Hortopan D, Podia-Igna C, Vizireanu A, Harsan T, Dumitriu L and Alexandrescu D: Late onset Graves' thyrotoxicosis in a patient with 18 years history of euthyroid Graves' ophthalmopathy. Acta Endo (Buc). 1:227–232. 2005.
43	Sarkar PK, Sarkar P, Acharjee U, Halder S, Sarkar S and Noatia C: Graves ophthalmopathy in a euthyroid patient-a rare case report. J Evol Med Dent Sci. 3:7150–7155. 2014.
44	Khan AA, Mahmoud Muammar AR and Kamal I: A case of unilateral exophthalmos due to thyroid orbitopathy in a clinically euthyroid patient. World J Res Rev. 9:1–3. 2019.
45	Suzuki N, Noh JY, Kameda T, Yoshihara A, Ohye H, Suzuki M, Matsumoto M, Kunii Y, Iwaku K, Watanabe N, et al: Clinical course of thyroid function and thyroid associated-ophthalmopathy in patients with euthyroid Graves' disease. Clin Ophthalmol. 12:739–746. 2018.PubMed/NCBI View Article : Google Scholar
46	Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marinò M, et al: Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 382:341–352. 2020.PubMed/NCBI View Article : Google Scholar
47	Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA and Bahn RS: Randomized controlled trial of rituximab in patients with Graves' orbitopathy. J Clin Endocrinol Metab. 100:432–441. 2015.PubMed/NCBI View Article : Google Scholar
48	Hodgson NM and Rajaii F: Current understanding of the progression and management of thyroid associated orbitopathy: A systematic review. Ophthalmol Ther. 9:21–33. 2020.PubMed/NCBI View Article : Google Scholar